Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Operating Leases (2019 - 2025)

Assembly Biosciences (ASMB) has 7 years of Operating Leases data on record, last reported at $2.2 million in Q3 2025.

  • For Q3 2025, Operating Leases rose 1853.1% year-over-year to $2.2 million; the TTM value through Sep 2025 reached $2.2 million, up 1853.1%, while the annual FY2024 figure was $2.6 million, 134.22% up from the prior year.
  • Operating Leases reached $2.2 million in Q3 2025 per ASMB's latest filing, down from $2.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $5.6 million in Q1 2021 and bottomed at $50000.0 in Q3 2023.
  • Average Operating Leases over 5 years is $1.9 million, with a median of $1.8 million recorded in 2022.
  • Peak YoY movement for Operating Leases: plummeted 96.96% in 2022, then surged 1853.1% in 2025.
  • A 5-year view of Operating Leases shows it stood at $3.3 million in 2021, then tumbled by 96.96% to $101000.0 in 2022, then soared by 1010.89% to $1.1 million in 2023, then soared by 134.22% to $2.6 million in 2024, then decreased by 16.02% to $2.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $2.2 million in Q3 2025, $2.4 million in Q2 2025, and $2.5 million in Q1 2025.